GO
Loading...

GPC Prostate Drug Needs More Data, FDA Panel Says

Reuters
Tuesday, 24 Jul 2007 | 5:13 PM ET

U.S. regulators should wait for final survival data before deciding whether to approve
GPC Biotech's proposed prostate cancer pill Orplatna, an advisory panel said on Tuesday in a 12-0 vote.

The Food and Drug Administration usually follows panel recommendations. The agency is expected to make a final decision on whether to clear Orplatna by mid-August.

Featured

Contact Health Care

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More